vs
Side-by-side financial comparison of OLAPLEX HOLDINGS, INC. (OLPX) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
OLAPLEX HOLDINGS, INC. is the larger business by last-quarter revenue ($105.1M vs $103.7M, roughly 1.0× Twist Bioscience Corp). OLAPLEX HOLDINGS, INC. runs the higher net margin — -12.5% vs -29.4%, a 17.0% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 4.3%). OLAPLEX HOLDINGS, INC. produced more free cash flow last quarter ($32.6M vs $-34.8M).
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
OLPX vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $105.1M | $103.7M |
| Net Profit | $-13.1M | $-30.5M |
| Gross Margin | 68.0% | 52.0% |
| Operating Margin | -4.3% | -31.7% |
| Net Margin | -12.5% | -29.4% |
| Revenue YoY | 4.3% | 16.9% |
| Net Profit YoY | -48.9% | 3.4% |
| EPS (diluted) | $-0.02 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $105.1M | $103.7M | ||
| Q3 25 | $114.6M | — | ||
| Q2 25 | $106.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $100.7M | — | ||
| Q3 24 | $119.1M | — | ||
| Q2 24 | $103.9M | — | ||
| Q1 24 | $98.9M | — |
| Q4 25 | $-13.1M | $-30.5M | ||
| Q3 25 | $11.1M | — | ||
| Q2 25 | $-7.7M | — | ||
| Q1 25 | $465.0K | — | ||
| Q4 24 | $-8.8M | — | ||
| Q3 24 | $14.8M | — | ||
| Q2 24 | $5.8M | — | ||
| Q1 24 | $7.7M | — |
| Q4 25 | 68.0% | 52.0% | ||
| Q3 25 | 69.1% | — | ||
| Q2 25 | 71.2% | — | ||
| Q1 25 | 69.5% | — | ||
| Q4 24 | 66.3% | — | ||
| Q3 24 | 68.6% | — | ||
| Q2 24 | 69.7% | — | ||
| Q1 24 | 72.1% | — |
| Q4 25 | -4.3% | -31.7% | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | -1.1% | — | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 23.5% | — | ||
| Q2 24 | 15.7% | — | ||
| Q1 24 | 19.8% | — |
| Q4 25 | -12.5% | -29.4% | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | -7.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | -8.7% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 7.8% | — |
| Q4 25 | $-0.02 | $-0.50 | ||
| Q3 25 | $0.02 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.01 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $318.7M | $197.9M |
| Total DebtLower is stronger | $352.3M | — |
| Stockholders' EquityBook value | $879.4M | $456.1M |
| Total Assets | $1.5B | $638.1M |
| Debt / EquityLower = less leverage | 0.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $318.7M | $197.9M | ||
| Q3 25 | $286.4M | — | ||
| Q2 25 | $289.3M | — | ||
| Q1 25 | $580.9M | — | ||
| Q4 24 | $586.0M | — | ||
| Q3 24 | $538.8M | — | ||
| Q2 24 | $507.9M | — | ||
| Q1 24 | $507.5M | — |
| Q4 25 | $352.3M | — | ||
| Q3 25 | $352.1M | — | ||
| Q2 25 | $351.9M | — | ||
| Q1 25 | $649.1M | — | ||
| Q4 24 | $650.5M | — | ||
| Q3 24 | $651.8M | — | ||
| Q2 24 | $653.1M | — | ||
| Q1 24 | $654.4M | — |
| Q4 25 | $879.4M | $456.1M | ||
| Q3 25 | $888.7M | — | ||
| Q2 25 | $874.2M | — | ||
| Q1 25 | $878.3M | — | ||
| Q4 24 | $874.4M | — | ||
| Q3 24 | $879.7M | — | ||
| Q2 24 | $863.3M | — | ||
| Q1 24 | $855.7M | — |
| Q4 25 | $1.5B | $638.1M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $1.8B | — |
| Q4 25 | 0.40× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.7M | $-24.8M |
| Free Cash FlowOCF − Capex | $32.6M | $-34.8M |
| FCF MarginFCF / Revenue | 31.0% | -33.5% |
| Capex IntensityCapex / Revenue | 0.1% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.7M | $-24.8M | ||
| Q3 25 | $8.0M | — | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $-2.9M | — | ||
| Q4 24 | $49.7M | — | ||
| Q3 24 | $33.5M | — | ||
| Q2 24 | $16.2M | — | ||
| Q1 24 | $43.7M | — |
| Q4 25 | $32.6M | $-34.8M | ||
| Q3 25 | $7.9M | — | ||
| Q2 25 | $20.8M | — | ||
| Q1 25 | $-3.0M | — | ||
| Q4 24 | $49.2M | — | ||
| Q3 24 | $33.3M | — | ||
| Q2 24 | $16.1M | — | ||
| Q1 24 | $43.3M | — |
| Q4 25 | 31.0% | -33.5% | ||
| Q3 25 | 6.9% | — | ||
| Q2 25 | 19.6% | — | ||
| Q1 25 | -3.1% | — | ||
| Q4 24 | 48.9% | — | ||
| Q3 24 | 28.0% | — | ||
| Q2 24 | 15.5% | — | ||
| Q1 24 | 43.7% | — |
| Q4 25 | 0.1% | 9.6% | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -6.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 2.81× | — | ||
| Q1 24 | 5.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
